File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Viral hepatitis B

TitleViral hepatitis B
Authors
Issue Date2003
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
Lancet, 2003, v. 362 n. 9401, p. 2089-2094 How to Cite?
AbstractMore than 400 million people worldwide are chronically infected by the hepatitis B virus. The virus is responsible for more than 300 000 cases of liver cancer every year and for similar numbers of gastrointestinal haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis and treatment of this virus. Hepatitis B vaccine reduces incidence of liver cancer. As with hepatitis C, advances have been made in molecular virology, especially for naturally occurring and treatment-induced mutant viruses. The clinical significance of low viral load and genotypes are also under investigation. Currently available monotherapies - interferon, lamivudine, and adefovir dipivoxil - very rarely eradicate the virus, but greatly reduce its replication, necroinflammatory histological activity, and progression of fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse cirrhosis of the liver.
Persistent Identifierhttp://hdl.handle.net/10722/76702
ISSN
2015 Impact Factor: 44.002
2015 SCImago Journal Rankings: 14.638
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorRatziu, Ven_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorPoynard, Ten_HK
dc.date.accessioned2010-09-06T07:24:02Z-
dc.date.available2010-09-06T07:24:02Z-
dc.date.issued2003en_HK
dc.identifier.citationLancet, 2003, v. 362 n. 9401, p. 2089-2094en_HK
dc.identifier.issn0140-6736en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76702-
dc.description.abstractMore than 400 million people worldwide are chronically infected by the hepatitis B virus. The virus is responsible for more than 300 000 cases of liver cancer every year and for similar numbers of gastrointestinal haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis and treatment of this virus. Hepatitis B vaccine reduces incidence of liver cancer. As with hepatitis C, advances have been made in molecular virology, especially for naturally occurring and treatment-induced mutant viruses. The clinical significance of low viral load and genotypes are also under investigation. Currently available monotherapies - interferon, lamivudine, and adefovir dipivoxil - very rarely eradicate the virus, but greatly reduce its replication, necroinflammatory histological activity, and progression of fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse cirrhosis of the liver.en_HK
dc.languageengen_HK
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lanceten_HK
dc.relation.ispartofLanceten_HK
dc.subject.meshAdenine - analogs & derivatives - pharmacology - therapeutic useen_HK
dc.subject.meshAntiviral Agents - pharmacology - therapeutic useen_HK
dc.subject.meshComorbidityen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHIV Infections - drug therapy - epidemiologyen_HK
dc.subject.meshHepatitis B - drug therapy - epidemiology - virologyen_HK
dc.subject.meshHepatitis B virus - drug effects - genetics - isolation & purificationen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - epidemiology - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - pharmacology - therapeutic useen_HK
dc.subject.meshLamivudine - pharmacology - therapeutic useen_HK
dc.subject.meshPhosphonic Acidsen_HK
dc.subject.meshReverse Transcriptase Inhibitors - pharmacology - therapeutic useen_HK
dc.subject.meshViral Loaden_HK
dc.titleViral hepatitis Ben_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0140-6736&volume=362&spage=2089&epage=2094&date=2003&atitle=Viral+Hepatitis+Ben_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0140-6736(03)15108-2en_HK
dc.identifier.pmid14697813en_HK
dc.identifier.scopuseid_2-s2.0-0346765512en_HK
dc.identifier.hkuros87521en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0346765512&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume362en_HK
dc.identifier.issue9401en_HK
dc.identifier.spage2089en_HK
dc.identifier.epage2094en_HK
dc.identifier.isiWOS:000187429600027-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridRatziu, V=7004350599en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridPoynard, T=7103155394en_HK
dc.identifier.citeulike8695649-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats